Activist investor William Ackman on Monday said there will be no "crown jewel" asset sales at Valeant Pharmaceuticals International Inc. (VRX), but that the company would consider the sale on non core assets.

Mr. Ackman, who holds a board seat at the drug company, also told CNBC in an interview that Valeant's board "absolutely" would take up the issue of potential roll backs to some of the company's drug prices. The Valeant board, he said, would take up the issue "promptly."

The Pershing Square Holdings Ltd. chief executive also said that a renaming of the company is a possibility.

CNBC website: www.cnbc.com

Write to nymonitoring@dowjones.com

(END) Dow Jones Newswires

May 02, 2016 13:19 ET (17:19 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Pershing Square (EU:PSH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Pershing Square.
Pershing Square (EU:PSH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Pershing Square.